Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study
about
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study
description
im Januar 2015 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 January 2015
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2014
@uk
name
Clinical benefits of non-taxan ...... docetaxel: the GETUG-P02 study
@en
Clinical benefits of non-taxan ...... docetaxel: the GETUG-P02 study
@nl
type
label
Clinical benefits of non-taxan ...... docetaxel: the GETUG-P02 study
@en
Clinical benefits of non-taxan ...... docetaxel: the GETUG-P02 study
@nl
prefLabel
Clinical benefits of non-taxan ...... docetaxel: the GETUG-P02 study
@en
Clinical benefits of non-taxan ...... docetaxel: the GETUG-P02 study
@nl
P2093
P50
P356
P1433
P1476
Clinical benefits of non-taxan ...... docetaxel: the GETUG-P02 study
@en
P2093
Alexandra Leconte
Aline Guillot
Bruno Valenza
Bénédicte Clarisse
Claude Linassier
Emmanuel Sevin
Emmanuelle Bompas
François Ringensen
Jean-Christophe Eymard
Lionel Vedrine
P356
10.1111/BJU.12552
P577
2015-01-01T00:00:00Z